Home | Welcome to Contract Pharma   
Last Updated Saturday, May 18 2013
Print

Financial Reports: Covance 1Q



By Gil Roth



Published May 3, 2012
Covance 1Q12

1Q Revenues: $531 million (+7%)

1Q Earnings: $36 million (+9%)

Comments: Early Development Services dropped 6% to $212 million due to lower than expected volumes in box and discovery support services, while Late-Stage Development was up 15% to $319 million with a 25% growth in clinical development and 4% uptick in central laboratory services. The company announced plans to close a facility in Chandler, AZ and engage in other Early Development restructurings to improve earnings by $20 million. Tox room capacities will drop to 2007 levels. The company is considering further cost cuts if the Early Development situation doesn't improve.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On